You may view the teleconference materials by clicking on the link below.
Sidley’s Antitrust and Global Life Sciences teams invite you to join us for a teleconference on the European Commission’s preliminary findings in its far-reaching pharma sector antitrust inquiry. We will address the impact of these findings on the pharmaceutical industry, the next steps in the inquiry procedure, and the ways companies can help shape the outcome.
Topics that will be addressed include:
- a critique of the Commission’s suggestion that product life cycle management strategies may violate competition laws;
- whether, and the extent to which, the Commission’s report represents a divergence from
U.S. law regarding so-called “pay-to-delay” patent settlements between researched-based
and generic drug companies;
- whether U.S. law on that subject can appropriately provide guidance to the Commission in
light of different regulatory regimes governing generic entry;
- the tensions between the Commission’s suspicions regarding collaborations between drug
companies and the perception in the pharmaceutical industry of greater market risk; and
- the extent to which the Commission’s report suggests hostility, or an attempt to displace,
traditional intellectual property principles.
About the speakers:
With leading global practices in both Antitrust and Life Sciences, Sidley is especially well-placed to advise pharmaceutical companies on the implications of the current EU pharmaceutical sector inquiry, and similar government actions around the globe. Ms. Nordlander and Mr. Spinks both have broad experience counseling pharmaceutical clients on EU antitrust and regulatory issues. Drawing on their close contacts and excellent reputation with the European regulators, they will share their in-depth understanding of the EU’s preliminary findings and discuss the potentially far-reaching impact of this investigation on global pharmaceutical companies. Mr. Treece brings to the discussion decades of experience representing some of the world’s largest pharmaceutical companies on “bet-the-company” antitrust investigations and litigation in the U.S. He is recognized as one of the leading antitrust lawyers in the country and speaks widely on antitrust issues, in particular with respect to the pharmaceutical sector. This panel offers valuable insight and comparative analysis of the current antitrust enforcement landscape on both sides of the Atlantic.